Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to tame pituitary tumors with fewer side effects

NCT ID NCT06826170

Disease control Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tumor growth while reducing damage to nearby nerves and the pituitary gland. Twenty-five patients were followed for at least a year with MRI scans, eye tests, and hormone checks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypofractionated stereotactic radiotherapy (radiation therapy given in 5 daily sessions)
What this could lead to
If successful, this approach could offer a safer way to treat residual or recurrent pituitary tumors with fewer side effects on vision and hormone function.
What could go wrong
This is a small, early-phase study with only 25 participants. It may not confirm long-term safety or effectiveness, and some patients may still experience side effects or tumor progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Sep 2020

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Residual or progressive non secreting pituitary adenoma; * Exclusion of other treatment approach (second surgery, wait and scan; suppressive therapy) by a multidisciplinary team * Age ≥ 18 years; KPS ≥ 70 * Written privacy consent; * Ability to give informed consent; Exclusion Criteria: * Previous cranial irradiation; * Diagnosis of secreting adenoma; * pregnancy status; * unable to undergo MRI or CT scans; * unable to give informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-secreting pituitary adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-functioning pituitary adenoma pituitary gland adenoma Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pituitary adenoma Pituitary neoplasms

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Neurologico C Besta

    Milan, Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.